Cns Pharmaceuticals Inc Dossier - Source-backed chat

Cns Pharmaceuticals Inc

CNSPNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)1.01

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $5.24Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $7.7M

Enterprise Value $689.8K

Shares Outstanding 1.5M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

CNS Pharmaceuticals is undergoing a complete corporate transformation under a newly appointed executive team led by CEO Rami Levin. The company has pivoted away from its legacy glioblastoma programs (Berubicin and TPI-287) following clinical data showing Berubicin failed to demonstrate superiority over lomustine in overall survival. CNS is now transitioning to an acquisition-driven growth model focused on in-licensing or acquiring differentiated clinical-stage neurology and oncology assets. While a recently completed $22.5 million private placement shored up liquidity and extended the cash runway beyond 12 months, the stock remains a high-risk, pre-revenue play. Investors should maintain a Hold stance until the new management team successfully executes its first major asset acquisition and establishes a clear clinical development pathway.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$10.00

Mean target$10.00

High · most bullish analyst$10.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The company struggles to identify or acquire high-quality assets, leading to prolonged cash burn on administrative expenses. Efforts to out-license Berubicin and TPI-287 fail, resulting in complete write-downs. The company is forced to raise highly dilutive capital or faces Nasdaq delisting risks as the cash runway depletes.

Base CaseCentral scenario

The company successfully utilizes its $22.5 million cash buffer to acquire or in-license a promising Phase 1 or Phase 2 clinical asset in neurology or oncology. Legacy assets are out-licensed, providing modest non-dilutive milestone payments. The stock stabilizes as the market gains visibility into the new pipeline's clinical timeline.

Bull CaseUpside scenario

The successful closing of the $22.5 million private placement in May 2026 provides a solid capital foundation, extending the operational runway beyond 12 months and allowing the newly assembled executive team to execute its strategic pivot toward acquiring high-value, clinical-stage neurology and oncology assets with near-term catalysts.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Substantial near-term liquidity shored up by an oversubscribed $22.5 million private placement closed in May 2026.
Experienced, newly assembled executive leadership team with deep expertise in neurology, oncology, and rare disease drug development.
Active pursuit of non-dilutive funding through the out-licensing of legacy glioblastoma assets.

Key Investment Risks

High execution risk associated with the transition to an acquisition-driven business model with no current lead clinical asset.
Potential market overhang and dilution from the resale registration of up to 9.79 million shares of common stock linked to the May 2026 private placement.
Historical track record of high cash burn and lack of product revenue.

Thesis Invalidation Triggers

Failure to secure a new lead clinical asset within the next 12 months.
Inability to out-license legacy glioblastoma assets, leading to a total write-off of historical R&D investments.
Rapid depletion of the $22.5 million cash reserve on G&A expenses without clinical progress.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.